Last news
- Ermium Therapeutics strengthen its leadership team with the recent appointment of Dr Hélène Asnagli as head of biology / pharmacology
- Ermium Therapeutics to present promising preclinical data highlighting the therapeutic potential of Ermium immunomodulators for the treatment of systemic lupus erythematosus at the annual ACR Convergence 2022 conference
- CXCR4 as a novel target in immunology: moving away from typical antagonists
- Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M
- Formation of a Scientific Advisory Board
- Ermium Therapeutics at the Biotech Showcase
